Allurion raises ~$6.1M via registered direct offering and private placement to fund GLP-1 clinical pipeline

ALLURION TECHNOLOGIES, INC.

Issued 900,000 shares of common stock at $5.23/share and 1,800,000 warrants (exercise $5.23, 5-year term, exercisable only after stockholder approval).
Also issued 267,686 shares and 535,372 warrants to Leavitt Equity Partners at $5.23/share in a concurrent private placement.
Total gross proceeds expected to be ~$6.1M; net proceeds will fund muscle mass/GLP-1 adherence trials, working capital, and general corporate purposes.
As consideration, company will seek stockholder approval to reduce exercise price of Leavitt’s July 2024 warrants from $30.00 to $6.00 per share.
Offering closed on February 20, 2025; Roth Capital Partners acted as exclusive placement agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.